Oncoinvent ASA: Ex. reverse share split and change of ISIN today

Oncoinvent ASA announced a 100:1 reverse share split effective 19 January 2026 with a new par value of NOK 50, a new ISIN (NO0013711713) and a post-split share count of 4,478,412 outstanding. The corporate action, disclosed under Euronext Oslo rules, consolidates the capital structure and updates the company's ISIN while Oncoinvent continues as a clinical-stage biotech developing Radspherin® (radium-224 radiopharmaceutical) in ongoing Phase 2 and earlier trials. The change is administrative and technical in nature but may affect trading mechanics, per‑share pricing and liquidity for shareholders. Contact: CEO Oystein Soug ([e-mail]).

Analysis

Market-structure: The 100:1 reverse split (new share count 4,478,412 from ~447.8M) is a liquidity/compliance maneuver that lifts nominal price and concentrates free float. Short-term winners: large existing holders (lower administrative friction) and issuers seeking institutional interest; losers: retail odd-lot holders, market makers facing wider spreads and higher quoted volatility. Expect immediate volatility and thinner daily volume (tradeable float likely down by >30% if small holders exit).

Competitive dynamics & supply/demand: No change to enterprise value or clinical program fundamentals, but the psychological price increase may reduce frictional supply and temporarily boost bid-side demand from funds with minimum price rules. However, split often precedes capital raises — signalling potential near-term dilution; if the company issues >NOK 200–300m equity within 60–120 days expect >20–30% dilution and downward pressure.

Risk assessment & catalysts: Tail risks include negative Phase 2 readout (binary, >50% downside), regulatory safety flags around radium-224, or a dilutive rights issue that triggers selling. Near-term (days) risk = illiquidity and price gaps; short-term (weeks–months) risk = financing terms; long-term (quarters–years) risk = trial outcomes, partnership or commercialization failure. Watch for financing announcements, trial data windows, manufacturing inspection reports in next 30–180 days.

Trade/reaction framing (contrarian): Consensus will read the split as neutral/technical; a contrarian play is to buy a small, event-driven stake ahead of a financing announcement if pricing looks favourable (<NOK 1.00 post-split) and hedge with sector instruments. Conversely, short or buy protective puts only when clear dilution terms (>25%) are announced. Historical microcap reverse-splits show bimodal outcomes — either stabilization plus capital injection (price recovers 1.5–3x) or continued attrition after dilutive financing (>50% loss).

Key Decisions for Investors

• Establish a tactical long position in Oncoinvent ASA (Oslo) sized 0.5–1.0% of NAV using limit orders only after 3–7 trading days post-split to avoid opening volatility; set hard stop-loss at -35% and a take-profit at +100% within 3 months if a positive financing/partnership catalyst appears.
• Prepare a contingent short (or buy put options/puts on a CFD) sized 0.5% NAV if the company announces an equity financing >NOK 200m or dilution >25% within 60–120 days; enter within 48 hours of terms announcement and target interim gain of 25–50% or tighten on signs of stabilization.
• Hedge any Oncoinvent exposure with a 1–2% overweight to large-cap radiopharma/healthcare: buy Novartis (NVS) or Roche (RHHBY/ROG.SWX) to reduce idiosyncratic trial/dilution risk while keeping sector upside; rebalance if Oncoinvent passes Phase 2 readout or issues no new shares in 120 days.
• Do not trade options on Oncoinvent directly unless liquid strikes exist; instead buy 3-month put spreads on small-cap biotech indices or IBB (size 0.5% NAV) as tail-risk insurance ahead of the Phase 2 readout expected within 3–12 months.
• Monitor four triggers in next 30–180 days and act within 48 hours: (1) financing size/price, (2) Phase 2 enrollment/readout windows, (3) manufacturing/inspector findings, (4) any M&A/licensing approaches — each should change position sizing rules above.